BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Romosozumab-aqqg

Potential Risk of Myocardial Infarction, Stroke and Cardiovascular Death

  • EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death.¬†EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued.

Patient Counseling Information

Medication Guides

Patient Medication Guide - Evenity

Package Inserts

Romosozumab-aqqg

Updated April 2019